Abstract
The development of highly sensitive, selective and multiplex sensors has become an important challenge for disease diagnosis. In this study, we describe a multiplex biosensor for the detection of cancer biomarkers based on unique plasmon response of single gold nanoparticles (AuNPs) and antibody-antigen binding activity. To demonstrate the ability of the plasmon biosensor to detect and quantify cancer biomarkers: a panel of biomarkers, including α-fetoprotein (AFP), carcinoembryonic antigen (CEA) and prostate specific antigen (PSA) was used as a model analyte for multiple detection. A novel and sensitive multiplex biosensor was developed by immobilizing plasmonic nanoparticles in a site-specific manner and functionalized with monoclonal antibodies that recognize the target protein on hydrophilic-hydrophobic patterned glass slide. The proposed multi-analyte biosensor exhibited outstanding selectivity and sensitivity. The limit of detection was determined to be 91. fM, 94. fM and 10. fM for AFP, CEA and PSA from patient-mimicked serum, respectively. Finally, using this sensing strategy, this platform presents an excellent approach for versatile molecular diagnostics in both research and clinical medical fields.
| Original language | English |
|---|---|
| Pages (from-to) | 341-346 |
| Number of pages | 6 |
| Journal | Biosensors and Bioelectronics |
| Volume | 74 |
| DOIs | |
| Publication status | Published - 2015 Dec 5 |
Bibliographical note
Publisher Copyright:© 2015 Elsevier B.V..
Keywords
- Cancer biomarkers
- Gold nanoparticles
- Localized surface plasmon resonance
- Multiplex detection
ASJC Scopus subject areas
- Biotechnology
- Biophysics
- Biomedical Engineering
- Electrochemistry
